한글목차

세포 분석 시장 - 리포트의 범위

세계의 세포 분석 시장에 관한 TMR의 리포트는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 연구하고 있습니다. 2023년을 기준년, 2031년을 예측년으로서 2017-2031년 세계의 세포 분석 시장의 매출을 제공합니다. 또한 2023-2031년 세계의 세포 분석 시장의 연평균 성장률(CAGR %)도 제공합니다.

이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 시행되고, 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 진행했습니다. 2차 조사에는 세포 분석 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서를 참조하는 것이 포함됩니다.

이 리포트는 세계의 세포 분석 시장의 경쟁 구도를 상세 분석하고 있습니다. 세계의 세포 분석 시장에서 활동하는 주요 기업이 식별되고, 이 각각이 다양한 속성의 측면에서 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 세포 분석 시장에서 기업의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 시장 개요

• 개요
• 시장 역학
• 주요 바이오테크놀러지 기업과 제약기업의 치료 분야별 연구개발비의 개요

제4장 세계의 세포 분석 시장 분석과 예측 : 최종사용자별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 최종사용자별, 2017-2031
  • 바이오테크놀러지 및 제약회사
  • 학술계
  • 화장품 산업
  • 임상시험수탁기관
  • 수탁 개발·제조 조직

제5장 세계 시장의 분석과 예측 : 치료 영역별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 치료 영역별, 2015-2031
  • 종양학 및 종양 면역학
    • 저분자
    • 단백질 기반 치료법
    • 세포치료
    • 핵산 의약품
  • 심혈관질환 및 대사질환
    • 저분자
    • 단백질 기반 치료법
    • 세포치료
    • 핵산 의약품
  • 면역학
    • 저분자
    • 단백질 기반 치료법
    • 세포치료
    • 핵산 의약품
  • 희귀질환
    • 저분자
    • 단백질 기반 치료법
    • 세포치료
    • 핵산 의약품
  • 신경질환
    • 저분자
    • 단백질 기반 치료법
    • 세포치료
    • 핵산 의약품
  • 기타
    • 저분자
    • 단백질 기반 치료법
    • 세포치료
    • 핵산 의약품

제6장 세계 시장의 분석과 예측 : 테크놀러지별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 테크놀러지별, 2017-2031
  • 유세포분석
  • 영상 기반 사이토메트리
  • 생화학적 어세이
  • 질량분석법

제7장 세계 시장의 분석과 예측 : 워크플레이스별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 워크플레이스별, 2017-2031
  • 타깃 식별
  • 히트 생성과 리드 식별
  • 리드의 최적화
  • 인비트로 전임상 연구
  • 인비보 전임상 연구
  • 임상 연구

제8장 세계 시장의 분석과 예측 : 국가/지역별

• 주요 조사 결과
• 시장 금액 예측 : 국가/지역별, 2017-2031
  • 미국
  • 유럽
  • 중국
  • 세계의 기타 지역

제9장 미국의 세포 분석 시장 분석과 예측

제10장 유럽의 세포 분석 시장 분석과 예측

제11장 중국의 세포 분석 시장 분석과 예측

제12장 세계의 기타 지역의 세포 분석 시장 분석과 예측

영문목차

Cell Analysis Market - Scope of Report

TMR's report on the global cell analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell analysis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell analysis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell analysis market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell analysis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell analysis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell analysis market.

The report delves into the competitive landscape of the global cell analysis market. Key players operating in the global cell analysis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell analysis market profiled in this report.

Key Questions Answered in Global Cell Analysis Market Report:

• What is the sales/revenue generated by cell analysis across all regions during the forecast period?
• What are the opportunities in the global cell analysis market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cell Analysis Market - Research Objectives and Research Approach

The comprehensive report on the global cell analysis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell analysis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell analysis market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Key Research Objectives

2. Assumptions and Research Methodology

3. Market Overview

• 3.1. Overview
• 3.2. Market Dynamics
  • 3.2.1. Drivers
  • 3.2.2. Restraints
  • 3.2.3. Opportunities
• 3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
  • 3.3.1. Top 15 Origins of Pipeline Drugs
  • 3.3.2. Biological versus non-biological drugs as a % of pipeline
  • 3.3.3. Ongoing rise of gene and cell therapy

4. Global Cell Analysis Market Analysis and Forecast, by End-user

• 4.1. Introduction & Definition
• 4.2. Key Findings/Developments
• 4.3. Market Value Forecast, by End-user, 2017-2031
  • 4.3.1. Biotechnology & Pharmaceutical Companies
  • 4.3.2. Academia
  • 4.3.3. Cosmetic Industry
  • 4.3.4. Contract Research Organizations
  • 4.3.5. Contract Development and Manufacturing Organizations

5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area

• 5.1. Introduction & Definition
• 5.2. Key Findings/Developments
• 5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
  • 5.3.1. Oncology & Immune-oncology
    • 5.3.1.1. Small Molecules
    • 5.3.1.2. Protein-based Therapeutics
    • 5.3.1.3. Cell Therapy
    • 5.3.1.4. Nucleic Acid-based Drugs
  • 5.3.2. Cardiovascular & Metabolic Diseases
    • 5.3.2.1. Small Molecules
    • 5.3.2.2. Protein-based Therapeutics
    • 5.3.2.3. Cell Therapy
    • 5.3.2.4. Nucleic Acid-based Drugs
  • 5.3.3. Immunology
    • 5.3.3.1. Small Molecules
    • 5.3.3.2. Protein-based Therapeutics
    • 5.3.3.3. Cell Therapy
    • 5.3.3.4. Nucleic Acid-based Drugs
  • 5.3.4. Rare Diseases
    • 5.3.4.1. Small Molecules
    • 5.3.4.2. Protein-based Therapeutics
    • 5.3.4.3. Cell Therapy
    • 5.3.4.4. Nucleic Acid-based Drugs
  • 5.3.5. Neurological Diseases
    • 5.3.5.1. Small Molecules
    • 5.3.5.2. Protein-based Therapeutics
    • 5.3.5.3. Cell Therapy
    • 5.3.5.4. Nucleic Acid-based Drugs
  • 5.3.6. Others
    • 5.3.6.1. Small Molecules
    • 5.3.6.2. Protein-based Therapeutics
    • 5.3.6.3. Cell Therapy
    • 5.3.6.4. Nucleic Acid-based Drugs

6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Technology, 2017-2031
  • 6.3.1. Flow Cytometry
  • 6.3.2. Image-based Cytometry
  • 6.3.3. Biochemical Assays
  • 6.3.4. Mass Spectrometry

7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Workplace, 2017-2031
  • 7.3.1. Target Identification
  • 7.3.2. Hit Generation & Lead Identification
  • 7.3.3. Lead Optimization
  • 7.3.4. In Vitro Preclinical Studies
  • 7.3.5. In Vivo Preclinical Studies
  • 7.3.6. Clinical Studies

8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Country/Region, 2017-2031
  • 8.2.1. U.S.
  • 8.2.2. Europe
  • 8.2.3. China
  • 8.2.4. Rest of the World

9. U.S. Cell Analysis Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast, by End-user, 2017-2031
  • 9.2.1. Biotechnology & Pharmaceutical Companies
  • 9.2.2. Academia
  • 9.2.3. Cosmetic Industry
  • 9.2.4. Contract Research Organizations
  • 9.2.5. Contract Development and Manufacturing Organizations
• 9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
  • 9.3.1. Oncology & Immune-oncology
    • 9.3.1.1. Small Molecules
    • 9.3.1.2. Protein-based Therapeutics
    • 9.3.1.3. Cell Therapy
    • 9.3.1.4. Nucleic Acid-based Drugs
  • 9.3.2. Cardiovascular & Metabolic Diseases
    • 9.3.2.1. Small Molecules
    • 9.3.2.2. Protein-based Therapeutics
    • 9.3.2.3. Cell Therapy
    • 9.3.2.4. Nucleic Acid-based Drugs
  • 9.3.3. Immunology
    • 9.3.3.1. Small Molecules
    • 9.3.3.2. Protein-based Therapeutics
    • 9.3.3.3. Cell Therapy
    • 9.3.3.4. Nucleic Acid-based Drugs
  • 9.3.4. Rare Diseases
    • 9.3.4.1. Small Molecules
    • 9.3.4.2. Protein-based Therapeutics
    • 9.3.4.3. Cell Therapy
    • 9.3.4.4. Nucleic Acid-based Drugs
  • 9.3.5. Neurological Diseases
    • 9.3.5.1. Small Molecules
    • 9.3.5.2. Protein-based Therapeutics
    • 9.3.5.3. Cell Therapy
    • 9.3.5.4. Nucleic Acid-based Drugs
  • 9.3.6. Others
    • 9.3.6.1. Small Molecules
    • 9.3.6.2. Protein-based Therapeutics
    • 9.3.6.3. Cell Therapy
    • 9.3.6.4. Nucleic Acid-based Drugs
• 9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
  • 9.4.1. Flow Cytometry
  • 9.4.2. Image-based Cytometry
  • 9.4.3. Biochemical Assays
  • 9.4.4. Mass Spectrometry
• 9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
  • 9.5.1. Target Identification
  • 9.5.2. Hit Generation & Lead Identification
  • 9.5.3. Lead Optimization
  • 9.5.4. In Vitro Preclinical Studies
  • 9.5.5. In Vivo Preclinical Studies
  • 9.5.6. Clinical Studies

10. Europe Cell Analysis Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by End-user, 2017-2031
  • 10.2.1. Biotechnology & Pharmaceutical Companies
  • 10.2.2. Academia
  • 10.2.3. Cosmetic Industry
  • 10.2.4. Contract Research Organizations
  • 10.2.5. Contract Development and Manufacturing Organizations
• 10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
  • 10.3.1. Oncology & Immune-oncology
    • 10.3.1.1. Small Molecules
    • 10.3.1.2. Protein-based Therapeutics
    • 10.3.1.3. Cell Therapy
    • 10.3.1.4. Nucleic Acid-based Drugs
  • 10.3.2. Cardiovascular & Metabolic Diseases
    • 10.3.2.1. Small Molecules
    • 10.3.2.2. Protein-based Therapeutics
    • 10.3.2.3. Cell Therapy
    • 10.3.2.4. Nucleic Acid-based Drugs
  • 10.3.3. Immunology
    • 10.3.3.1. Small Molecules
    • 10.3.3.2. Protein-based Therapeutics
    • 10.3.3.3. Cell Therapy
    • 10.3.3.4. Nucleic Acid-based Drugs
  • 10.3.4. Rare Diseases
    • 10.3.4.1. Small Molecules
    • 10.3.4.2. Protein-based Therapeutics
    • 10.3.4.3. Cell Therapy
    • 10.3.4.4. Nucleic Acid-based Drugs
  • 10.3.5. Neurological Diseases
    • 10.3.5.1. Small Molecules
    • 10.3.5.2. Protein-based Therapeutics
    • 10.3.5.3. Cell Therapy
    • 10.3.5.4. Nucleic Acid-based Drugs
  • 10.3.6. Others
    • 10.3.6.1. Small Molecules
    • 10.3.6.2. Protein-based Therapeutics
    • 10.3.6.3. Cell Therapy
    • 10.3.6.4. Nucleic Acid-based Drugs
• 10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
  • 10.4.1. Flow Cytometry
  • 10.4.2. Image-based Cytometry
  • 10.4.3. Biochemical Assays
  • 10.4.4. Mass Spectrometry
• 10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
  • 10.5.1. Target Identification
  • 10.5.2. Hit Generation & Lead Identification
  • 10.5.3. Lead Optimization
  • 10.5.4. In Vitro Preclinical Studies
  • 10.5.5. In Vivo Preclinical Studies
  • 10.5.6. Clinical Studies
• 10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.6.1. EU5
  • 10.6.2. U.K.
  • 10.6.3. Switzerland
  • 10.6.4. Rest of Europe

11. China Cell Analysis Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by End-user, 2017-2031
  • 11.2.1. Biotechnology & Pharmaceutical Companies
  • 11.2.2. Academia
  • 11.2.3. Cosmetic Industry
  • 11.2.4. Contract Research Organizations
  • 11.2.5. Contract Development and Manufacturing Organizations
• 11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
  • 11.3.1. Oncology & Immune-oncology
    • 11.3.1.1. Small Molecules
    • 11.3.1.2. Protein-based Therapeutics
    • 11.3.1.3. Cell Therapy
    • 11.3.1.4. Nucleic Acid-based Drugs
  • 11.3.2. Cardiovascular & Metabolic Diseases
    • 11.3.2.1. Small Molecules
    • 11.3.2.2. Protein-based Therapeutics
    • 11.3.2.3. Cell Therapy
    • 11.3.2.4. Nucleic Acid-based Drugs
  • 11.3.3. Immunology
    • 11.3.3.1. Small Molecules
    • 11.3.3.2. Protein-based Therapeutics
    • 11.3.3.3. Cell Therapy
    • 11.3.3.4. Nucleic Acid-based Drugs
  • 11.3.4. Rare Diseases
    • 11.3.4.1. Small Molecules
    • 11.3.4.2. Protein-based Therapeutics
    • 11.3.4.3. Cell Therapy
    • 11.3.4.4. Nucleic Acid-based Drugs
  • 11.3.5. Neurological Diseases
    • 11.3.5.1. Small Molecules
    • 11.3.5.2. Protein-based Therapeutics
    • 11.3.5.3. Cell Therapy
    • 11.3.5.4. Nucleic Acid-based Drugs
  • 11.3.6. Others
    • 11.3.6.1. Small Molecules
    • 11.3.6.2. Protein-based Therapeutics
    • 11.3.6.3. Cell Therapy
    • 11.3.6.4. Nucleic Acid-based Drugs
• 11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
  • 11.4.1. Flow Cytometry
  • 11.4.2. Image-based Cytometry
  • 11.4.3. Biochemical Assays
  • 11.4.4. Mass Spectrometry
• 11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
  • 11.5.1. Target Identification
  • 11.5.2. Hit Generation & Lead Identification
  • 11.5.3. Lead Optimization
  • 11.5.4. In Vitro Preclinical Studies
  • 11.5.5. In Vivo Preclinical Studies
  • 11.5.6. Clinical Studies

12. Rest of the World Cell Analysis Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by End-user, 2017-2031
  • 12.2.1. Biotechnology & Pharmaceutical Companies
  • 12.2.2. Academia
  • 12.2.3. Cosmetic Industry
  • 12.2.4. Contract Research Organizations
  • 12.2.5. Contract Development and Manufacturing Organizations
• 12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
  • 12.3.1. Oncology & Immune-oncology
    • 12.3.1.1. Small Molecules
    • 12.3.1.2. Protein-based Therapeutics
    • 12.3.1.3. Cell Therapy
    • 12.3.1.4. Nucleic Acid-based Drugs
  • 12.3.2. Cardiovascular & Metabolic Diseases
    • 12.3.2.1. Small Molecules
    • 12.3.2.2. Protein-based Therapeutics
    • 12.3.2.3. Cell Therapy
    • 12.3.2.4. Nucleic Acid-based Drugs
  • 12.3.3. Immunology
    • 12.3.3.1. Small Molecules
    • 12.3.3.2. Protein-based Therapeutics
    • 12.3.3.3. Cell Therapy
    • 12.3.3.4. Nucleic Acid-based Drugs
  • 12.3.4. Rare Diseases
    • 12.3.4.1. Small Molecules
    • 12.3.4.2. Protein-based Therapeutics
    • 12.3.4.3. Cell Therapy
    • 12.3.4.4. Nucleic Acid-based Drugs
  • 12.3.5. Neurological Diseases
    • 12.3.5.1. Small Molecules
    • 12.3.5.2. Protein-based Therapeutics
    • 12.3.5.3. Cell Therapy
    • 12.3.5.4. Nucleic Acid-based Drugs
  • 12.3.6. Others
    • 12.3.6.1. Small Molecules
    • 12.3.6.2. Protein-based Therapeutics
    • 12.3.6.3. Cell Therapy
    • 12.3.6.4. Nucleic Acid-based Drugs
• 12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
  • 12.4.1. Flow Cytometry
  • 12.4.2. Image-based Cytometry
  • 12.4.3. Biochemical Assays
  • 12.4.4. Mass Spectrometry
• 12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
  • 12.5.1. Target Identification
  • 12.5.2. Hit Generation & Lead Identification
  • 12.5.3. Lead Optimization
  • 12.5.4. In Vitro Preclinical Studies
  • 12.5.5. In Vivo Preclinical Studies
  • 12.5.6. Clinical Studies